Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

211,831-211,860 of 319,975

filter-aware
01
Slide 1
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
04
The slide uses a structured grid layout to present key value drivers.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style visualization to show drug development stages.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide highlights the mechanism of action targeting multiple HBV transcripts.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
10
The slide outlines study design for Part 1, 2, and 3 of a clinical trial for chronic hepatitis B (cHBV).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
11
Data presented at Global Hepatitis Summit 2023. Includes specific cohort N values and standard error (SE) in parentheses.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
12
The slide displays six longitudinal line charts representing different patient cohorts, with specific callouts for clinical outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
13
Clinical trial data showing individual patient responses over time.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
14
Data presented at EASL 2022. Shows correlation between T-cell activation and HBsAg reduction.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
15
The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and specific laboratory findings.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
16
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
17
The slide outlines a clinical trial timeline and key efficacy metrics for a chronic hepatitis B (cHBV) treatment.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
18
The slide outlines two parallel study arms with randomization at week 24.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
19
The slide details a specific licensing deal, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
20
The slide uses a three-column layout to highlight key value propositions.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
21
Includes a line chart for efficacy over time and two bar charts for pharmacokinetic concentrations in plasma vs liver.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
22
Includes IC50 value and IFN-y fold increase data.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
23
The slide uses a three-column layout to explain the scientific basis and product profile.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
24
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
25
Includes a schematic of the SARS-CoV-2 genome and protein structure, alongside specific drug development strategies.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
26
The slide uses a three-pillar framework to summarize the drug's value proposition.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
27
Includes financial metrics (cash balance, runway, burn) as context for the milestones.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
28
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
01
Slide 1
argenx SE | Investor Presentation Deck | 26 slidesargenx SE | Investor Presentation Deck | 26 slides · argenx
Conference presentation Investor relations Beat · Setup1 hit
02
argenx SE | Investor Presentation Deck | 26 slidesargenx SE | Investor Presentation Deck | 26 slides · argenx
Conference presentation Investor relations Beat · Setup1 hit